Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:01:11 EDT Tue 04 Jun 2024
Enter Symbol
or Name
USA
CA



Q:RIGL - RIGEL PHARMACEUTICALS INC - http://rigel.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RIGL - Q1.00.90·0.981.00.9746-0.0085-0.91,731.41,6001,3530.99  1.00  0.93471.77  0.71216:46:05Jun 0315 min RT 2¢

Recent Trades - Last 10 of 1353
Time ETExPriceChangeVolume
16:46:05Q0.9741-0.009100
16:25:30Q0.9453-0.03781,000
16:08:45Q0.9328-0.05035
16:02:53Q0.9746-0.0085896
16:02:49Q0.9746-0.0085301
16:02:45Q0.9746-0.0085230
16:02:41Q0.9746-0.0085468
16:02:19Q0.9746-0.00851,292
16:01:49Q0.9746-0.0085172
16:01:45Q0.9746-0.00852,304

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-06-03 08:13U:RIGLNews ReleaseRigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
2024-05-30 08:05U:RIGLNews ReleaseRigel to Present at the Jefferies Global Healthcare Conference
2024-05-23 17:00U:RIGLNews ReleaseRigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
2024-05-07 16:01U:RIGLNews ReleaseRigel Reports First Quarter 2024 Financial Results and Provides Business Update
2024-04-30 08:05U:RIGLNews ReleaseRigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
2024-04-10 16:30U:RIGLNews ReleaseRigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-04-04 08:05U:RIGLNews ReleaseRigel Announces Publication of Data on REZLIDHIA(TM) (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
2024-03-12 08:05U:RIGLNews ReleaseRigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
2024-03-05 16:01U:RIGLNews ReleaseRigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-27 08:05U:RIGLNews ReleaseRigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
2024-02-22 07:50U:RIGLNews ReleaseRigel Pharmaceuticals Acquires U.S. Rights to GAVRETO ‚ ®
2024-01-08 08:05U:RIGLNews ReleaseRigel Pharmaceuticals Provides Business Update
2024-01-05 16:30U:RIGLNews ReleaseRigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-01-04 08:05U:RIGLNews ReleaseRigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
2024-01-03 08:05U:RIGLNews ReleaseRigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-08 08:05U:RIGLNews ReleaseRigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA ‚ ® (Olutasidenib) in AML and Other Cancers
2023-11-07 16:01U:RIGLNews ReleaseRigel Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-06 08:05U:RIGLNews ReleaseRigel to Present at the Jefferies London Healthcare Conference
2023-11-02 09:27U:RIGLNews ReleaseRigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition
2023-10-31 08:05U:RIGLNews ReleaseRigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update